Rare diseases
Investigational molecules
Locations
Back to Germany19 clinical trials in Hochheim Am Main, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DNL952 in Adults with Late‑Onset Pompe Disease
GermanyA Study of S-606001 Added to Enzyme Replacement Therapy for Patients with Late-Onset Pompe Disease
GermanyGermanyLong-term Safety and Efficacy Study of JR-141 (Pabinafusp Alfa) for Male Patients with Hunter Syndrome (Mucopolysaccharidosis II)
GermanyGermanyStudy on the Safety and Effects of Cipaglucosidase Alfa and Miglustat for Children with Infantile-onset Pompe Disease
GermanyStudy on Long-Term Safety and Effects of DNL310 for Patients with Mucopolysaccharidosis Type II (MPS II)
GermanyEfficacy and safety of oral venglustat versus intravenous imiglucerase in children aged 2‑11 years with Gaucher disease type 3
GermanyStudy on the Safety of LY3884961 for Patients with Type 1 Gaucher Disease
GermanyStudy on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections
GermanyStudy comparing venglustat tablets with standard therapy for adult patients with Fabry disease and left ventricular hypertrophy
GermanyStudy on Long-Term Effects and Safety of Herpes Zoster Vaccine with Recombinant Varicella Zoster Virus Glycoprotein E in Older Adults
GermanyThe busiest research cities in the country
What the registry says about research in the country
Innovative research focusing on Gaucher disease and Niemann-Pick disease, exploring new therapeutic approaches for these challenging genetic conditions. Studies aim to evaluate novel treatments for improving neurological symptoms and overall patient outcomes.
Clinical investigations evaluating venglustat and nizubaglustat's effectiveness in managing disease progression.
Research centered on treating Mucopolysaccharidosis Type II (Hunter Syndrome) and Pompe disease, with multiple studies investigating innovative enzyme replacement therapies and novel drug combinations.
Evaluation of treatments like JR-141 and cipaglucosidase alfa for improved patient outcomes.
Studies focused on preventing respiratory syncytial virus infections in older adults, with particular attention to vaccine development and immune response assessment.
Investigation of revaccination strategies and long-term protection against respiratory infections.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
